Roche, Bio­gen hand­ing over $470M in cash to bag two drug pro­grams from Bris­tol-My­ers Squibb

Bris­tol-My­ers Squibb has forged a pair of sep­a­rate pacts with Roche and Bio­gen to out­li­cense two drugs, grab­bing a whop­ping $470 mil­lion up­front for the deals.

Bio­gen gets con­trol of BMS-986168, an an­ti-eTau com­pound in clin­i­cal de­vel­op­ment for Pro­gres­sive Supranu­clear Pal­sy, for $300 mil­lion up­front and $410 mil­lion in mile­stones. And Roche gets BMS-986089, an an­ti-myo­statin Ad­nectin in de­vel­op­ment for Duchenne mus­cu­lar dy­s­tro­phy. Roche is pay­ing $170 mil­lion plus $205 mil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.